From subtle rashes to sun-safety strategies, Drs Maureen McMahon and John Edminister discuss how to recognize cutaneous lupus and protect patients from UV-triggered flares.

The global cutaneous lupus erythematosus market is experiencing significant growth, driven by novel biologic therapies and personalized medicine. With rising autoimmune disease incidence, enhanced ...

Lupus, an autoimmune disorder, presents skin manifestations like the butterfly rash, often mimicked by conditions such as ...

Discover how butterfly rashes, purple spots, and other skin changes can reveal lupus, blood disorders, and serious diseases ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

About Enpatoran Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).

Lupus erythematosus is a heterogeneous autoimmune disorder that frequently manifests with distinctive cutaneous involvement. The cutaneous lesions, which range from a malar rash to more indurated ...

Self-advocacy and education are key to managing lupus and navigating the healthcare system. Mental health and reproductive health concerns are important but often under-addressed aspects of living ...

Share Lupus Foundation of America, Lone Star Chapter 13155 Noel Road, Suite 900 Dallas, TX 75240 972-919-6191 info@lupuslonestar.org Get lupus resources and updates. Subscribe to our emails.

Cohort A focused on patients with CLE or SLE with active lupus rash and evaluated organ-specific disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity ...